Clinuvel Pharmaceuticals Limited (ASX:CUV) Successful Drug Trial Results For Light Intolerant Shadow Jumpers
Results released today from a Phase III trial of the drug SCENESSE (R), conducted by Melbourne-based Clinuvel Pharmaceuticals Limited (ASX:CUV) (PINK:CLVLY), have shown that the drug has the ability to reduce and prevent painful phototoxic reactions experienced by patients with erythropoietic protoporphyria (EPP).